[A24-69] Fezolinetant (vasomotor symptoms in menopause) – Addendum to Project A24-15
Last updated 01.08.2024
Project no.:
A24-69
Commission:
Commission awarded on 11.06.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Reproductive health and birth
Indication:
Menopausal women with moderate to severe vasomotor symptoms
Result of dossier assessment:
- Patients for whom hormone therapy is an option and who have decided in favour of hormone replacement therapy after an individual risk-benefit assessment: added benefit not proven
- Patients for whom hormone therapy is not an option or those who have decided against therapy after an individual risk-benefit assessment: hint of considerable added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
DOI:
https://doi.org/10.60584/A24-69_en
| Project no. | Title | Status |
|---|---|---|
| A24-15 | Fezolinetant (vasomotor symptoms in menopause) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-08-01 A G-BA decision was published.